Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
Victor Jeannot(Centre National de la Recherche Scientifique), Amandine Hurbin(Centre National de la Recherche Scientifique)
Cited by 36
Related Papers
Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer
|Journal of Controlled Release|2018|88
The PI3K/AKT pathway promotes gefitinib resistance in mutant <i>KRAS</i> lung adenocarcinoma by a deacetylase‐dependent mechanism
|International Journal of Cancer|2013|57